Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Merz: 80% of Syrians in Germany should return in three years - 2The most effective method to Pick the Right Material Organization: Your Definitive Aide
- 3High-Suggested Broilers For Your Homes
- 4Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- 5National health ranking puts Georgia near bottom of list. Here's why
- 6 Nations for Setting up camp
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- Find the Specialty of Public Speaking: Drawing in and Convincing Crowds with Certainty
- Find Exemplary Scents: An Extensive Aide
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- Ukrainian drones hit all three Baltic States − did Russia redirect them?
- Some are walking out. Some are shouting. Some are oblivious. How kids are reacting to THAT 'Wicked: For Good' scene
- Becoming amazing at Systems administration: Individual and Expert Tips
- No more attempts to free whale stranded off Germany, officials say
